Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T05:00:31.122Z Has data issue: false hasContentIssue false
  • English
  • Français

Targeted Review: Medications for Acute Migraine Treatment

Published online by Cambridge University Press:  01 July 2015

Irene Worthington ,
Tamara Pringsheim ,
Marek J. Gawel ,
Jonathan Gladstone ,
Paul Cooper ,
Esma Dilli ,
Michel Aube ,
Elizabeth Leroux ,
Werner J. Becker  and
on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
Irene Worthington
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario
Tamara Pringsheim
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
Marek J. Gawel
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Rouge Valley Health System – Centenary, Toronto, Ontario Women's College Hospital, Toronto, Ontario, Canada
Jonathan Gladstone
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Gladstone Headache Clinic, Toronto, Ontario
Paul Cooper
Affiliation:
University of Western Ontario, London, Ontario
Esma Dilli
Affiliation:
University of British Columbia, Vancouver, British Columbia
Michel Aube
Affiliation:
McGill University, Montreal, Quebec
Elizabeth Leroux
Affiliation:
University of Montreal, Montreal, Quebec
Werner J. Becker*
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
*
Division of Neurology, 12th Floor, Foothills Hospital, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To assess the evidence base for drugs used for acute treatment of episodic migraine (headache on < 14 days a month) in Canada.

Methods:

A detailed search strategy was employed to find relevant published clinical trials of drugs used in Canada for the acute treatment of migraine in adults. Primarily meta-analyses and systematic reviews were included. Where these were not available for a drug or were out of date, individual clinical trial reports were utilized. Only double-blind randomized clinical trials with placebo or active drug controls were included in the analysis. Recommendations and levels of evidence were graded according to the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, using a consensus group.

Results:

Eighteen acute migraine medications and two adjunctive medications were evaluated. Twelve acute medications received a strong recommendation with supporting high quality evidence for use in acute migraine therapy (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ASA, ibuprofen, naproxen sodium, diclofenac potassium, and acetaminophen). Four acute medications received a weak recommendation for use with low or moderate quality evidence (dihydroergotamine, ergotamine, codeine-containing combination analgesics, and tramadol-containing combination analgesics). Three of these medications were NOT recommended for routine use (ergotamine, and codeine- and tramadol-containing medications), and strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Both metoclopramide and domperidone received a strong recommendation for use with acute migraine attack medications where necessary.

Conclusion:

Our targeted review formulated recommendations for the available acute medications for migraine treatment according to the GRADE method. This should be helpful for practitioners who prescribe medications for acute migraine treatment.

Type
SECTION II
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue S3 , September 2013 , pp. S10 - S32
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society.[see comment][erratum appears in CMAJ 1997 Nov 15;157(10):1354]. [Review] [160 refs]. CMAJ. 1997;156:1273–87.Google Scholar
2.Lipton, RB, Stewart, WF.Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39:S20–6.CrossRefGoogle Scholar
3.Guyatt, GH, Oxman, AD, Vist, GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.Google Scholar
4.Guyatt, GH, Oxman, AD, Kunz, R, et al.What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.CrossRefGoogle Scholar
5.Balshem, H, Helfand, M, Schunemann, HJ, et al.GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.CrossRefGoogle ScholarPubMed
6.Cuello Garcia, CA, Pacheco Alvarado, KP, Perez Gaxiola, G.Grading recommendations in clinical practice guidelines: randomised experimental evaluation of four different systems. Arch Dis Child. 2011;96:723–8.CrossRefGoogle ScholarPubMed
7.Brozek, JL, Akl, EA, Compalati, E, et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66:588–95.Google Scholar
8.Oldman, AD, Smith, LA, McQuay, HJ, Moore, RA.Pharmacological treatments for acute migraine: quantitative systematic review. Pain. 2002;97:247–57.Google Scholar
9.Johnston, MM, Rapoport, AM.Triptans for the management of migraine. Drugs. 2010;70:1505–18.Google Scholar
10.Dodick, D, Lipton, RB, Martin, V, et al.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. [Review] [66 refs]. Headache. 2004;44:414–25.CrossRefGoogle Scholar
11.Tepper, SJ, Millson, D.Safety profile of the triptans. [Review] [51 refs]. Expert Opin Drug Saf. 2003;2:123–32.Google Scholar
12.Wenzel, RG, Tepper, S, Korab, WE, Freitag, F.Serotonin syndrome risks when combining SSRI/SnRI drugs and triptans: is the FDA’S alert warranted? Ann Pharmacother. 2008;42:1692–6.Google Scholar
13.Gillman, PK.Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010;50:264–72.Google Scholar
14.Ferrari, MD, Goadsby, PJ, Roon, KI, Lipton, RB.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.[see comment][erratum appears in Cephalalgia. 2003 Feb;23(1):71.]. Cephalalgia. 2002;22:633–58.Google Scholar
15.Ferrari, MD, Roon, KI, Lipton, RB, Goadsby, PJ.Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. [see comment]. Lancet. 2001;358:1668–75.Google Scholar
16.Pascual, J, Mateos, V, Roig, C, Sanchez-Del-Rio, M, Jimenez, D.Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache. 2007;47:1152–68.CrossRefGoogle Scholar
17.Gawel, MJ, Worthington, I, Maggisano, A.A systematic review of the use of triptans in acute migraine. [see comment]. [Review] [74 refs]. Can J Neurol Sci. 2001;28:30–41.Google Scholar
18.Lipton, RB, Bigal, ME, Goadsby, PJ.Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. [Review] [35 refs]. Cephalalgia. 2004;24:321–32.CrossRefGoogle Scholar
19.Smith, TR, Sunshine, A, Stark, SR, Littlefield, DE, Spruill, SE, Alexander, WJ.Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983–91.Google Scholar
20.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443–54.Google Scholar
21.Mathew, NT, Landy, S, Stark, S, et al.Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49:971–82.Google Scholar
22.Vollono, C, Capuano, A, Mei, D, et al.Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol. 2005;12:557–63.Google Scholar
23.Dodick, DW.Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45:156–62.Google Scholar
24.Diener, HC, Gendolla, A, Gebert, I, Beneke, M.Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol. 2005;53:41–8.Google Scholar
25.Farkkila, M, Olesen, J, Dahlof, C, et al.Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23:463–71.CrossRefGoogle ScholarPubMed
26.Stark, S, Spierings, EL, Mcneal, S, Putnam, GP, Bolden-Watson, CP, O’Quinn, S.Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000;40:513–20.Google Scholar
27.Klapper, J, Lucas, C, Rosjo, O, Charlesworth, B, ZODIAC study g. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. [see comment]. Cephalalgia. 2004;24:918–24.Google Scholar
28.Cady, R, Elkind, A, Goldstein, J, Keywood, C.Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465–72.CrossRefGoogle ScholarPubMed
29.Brandes, JL, Kudrow, D, Cady, R, Tiseo, PJ, Sun, W, Sikes, CR.Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25:735–42.CrossRefGoogle ScholarPubMed
30.Barbanti, P, Carpay, JA, Kwong, WJ, Ahmad, F, Boswell, D.Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin. 2004;20:2021–9.CrossRefGoogle ScholarPubMed
31.Jelinski, SE, Becker, WJ, Christie, SN, Ahmad, FE, Pryse-Phillips, W, Simpson, SD.Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neur Sci. 2006;33:73–9.CrossRefGoogle ScholarPubMed
32.Cady, R, Martin, V, Mauskop, A, et al.Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46:914–24.Google Scholar
33.Winner, P, Mannix, LK, Putnam, DG, et al.Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78:1214–22.Google Scholar
34.Loder, E.Triptan therapy in migraine. N Engl J Med. 2010;363:63–70.CrossRefGoogle ScholarPubMed
35.Geraud, G, Keywood, C, Senard, JM.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376–88.CrossRefGoogle ScholarPubMed
36.Tfelt-Hansen, P, Saxena, PR, Dahlof, C, et al.Ergotamine in the acute treatment of migraine: a review and european consensus. [Review] [84 refs]. Brain. 2000;123:9–18.CrossRefGoogle Scholar
37.Anonymous Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache. 1995;35:177–84.Google Scholar
38.Treves, TA, Kuritzky, A, Hering, R, Korczyn, AD.Dihydroergotamine nasal spray in the treatment of acute migraine. Headache. 1998; 38:614–7.Google Scholar
39.Boureau, F, Kappos, L, Schoenen, J, esperanca, P, Ashford, E. Aclinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000;54:281–6.Google Scholar
40.Touchon, J, Bertin, L, Pilgrim, AJ, Ashford, E, Bes, A.A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47:361–5.CrossRefGoogle ScholarPubMed
41.Winner, P, Ricalde, O, Le Force, B, Saper, J, Margul, B.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. [see comment]. Arch Neurol. 1996;53:180–4.Google Scholar
42.Anonymous. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991;31:314–22.Google Scholar
43.Diener, HC, Jansen, JP, Reches, A, et al.Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47:99–107.Google Scholar
44.Dowson, AJ, Massiou, H, Lainez, JM, Cabarrocas, X.Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453–61.Google Scholar
45.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2012;2:008615.Google Scholar
46.Wenzel, RG, Sarvis, CA, Krause, ML.Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy. 2003;23:494–505.Google Scholar
47.Silberstein, S, Tepper, S, Brandes, J, et al.Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology. 2004;62:1552–7.Google Scholar
48.Misra, UK, Jose, M, Kalita, J.Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J. 2004;80:720–3.Google Scholar
49.Kirthi, V, Derry, S, Moore, RA, McQuay, HJ.Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;4:008041.Google Scholar
50.Lampl, C, Voelker, M, Diener, HC.Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–12.Google Scholar
51.Suthisisang, C, Poolsup, N, Kittikulsuth, W, Pudchakan, P, Wiwatpanich, P.efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41:1782–91.Google Scholar
52.Rabbie, R, Derry, S, Moore, RA, McQuay, HJ.Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008039.Google Scholar
53.Kellstein, DE, Lipton, RB, Geetha, R, et al.Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000;20:233–43.CrossRefGoogle ScholarPubMed
54.Misra, UK, Kalita, J, Yadav, RK.Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain. 2007;8:175–9.Google Scholar
55.Suthisisang, C, Poolsup, N, Suksomboon, N, Lertpipopmetha, V, Tepwitukgid, B.Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50:808–18.CrossRefGoogle ScholarPubMed
56.Mcneely, W, Goa, KL.Diclofenac-potassium in migraine: a review. Drugs. 1999;57:991–1003.CrossRefGoogle ScholarPubMed
57.Diener, HC, Montagna, P, Gacs, G, et al.Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537–47.Google Scholar
58.Lipton, RB, Grosberg, B, Singer, RP, et al.Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30:1336–45.Google Scholar
59.Derry, S, Rabbie, R, Moore, RA.Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2012;2:008783.Google ScholarPubMed
60.Anonymous Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenacpotassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia. 1999;19:232–40.Google Scholar
61.Diener, HC, Montagna, P, Gacs, G, et al.Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537–47.Google Scholar
62.Lipton, RB, Baggish, JS, Stewart, WF, Codispoti, JR, Fu, M.Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486–92.Google Scholar
63.Prior, MJ, Codispoti, JR, Fu, M.A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache. 2010;50:819–33.Google Scholar
64.Derry, S, Moore, RA, McQuay, HJ.Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2010;008040.Google Scholar
65.Silberstein, SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. [Review] [44 refs]. Headache. 2001;41:953–67.CrossRefGoogle Scholar
66.Boureau, F, Joubert, JM, Lasserre, V, Prum, B, Delecoeuillerie, G.Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156–61.Google Scholar
67.Loder, E.Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalalgia. 2006;26:89–97.Google Scholar
68.Hoffert, MJ, Couch, JR, Diamond, S, et al.Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35:65–9.Google Scholar
69.Goldstein, J, Gawel, MJ, Winner, P, et al.Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache. 1998;38:516–22.Google Scholar
70.Senay, EC, Adams, EH, Geller, A, et al.Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend. 2003;69: 233–41.Google Scholar
71.Raffa, RB.Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther. 2008;33:101–8.Google Scholar
72.Tjaderborn, M, Jonsson, AK, Ahlner, J, Hagg, S.Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf. 2009;18:1192–8.Google Scholar
73.Silberstein, SD, Freitag, FG, Rozen, TD, et al.Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005;45:1317–27.Google Scholar
74.Wenzel, RG, Sarvis, CA.Do butalbital-containing products have a role in the management of migraine? [Review] [55 refs]. Pharmacotherapy. 2002;22:1029–35.Google Scholar
75.Raja, M, Altavista, MC, Azzoni, A, Albanese, A.Severe barbiturate withdrawal syndrome in migrainous patients. Headache. 1996;36:119–21.CrossRefGoogle ScholarPubMed
76.Derosier, F, Sheftell, F, Silberstein, S, et al.Sumatriptan-naproxen and butalbital: A double-blind, placebo-controlled crossover study. Headache. 2012;52:530–43.Google Scholar
77.Geraud, G, Compagnon, A, Rossi, A, COZAM Study G. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol. 2002;47:88–98.CrossRefGoogle Scholar
78.Chabriat, H, Joire, JE, Danchot, J, Grippon, P, Bousser, MG.Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia. 1994;14:297–300.Google Scholar
79.Tfelt-Hansen, P, Henry, P, Mulder, LJ, Scheldewaert, RG, Schoenen, J, Chazot, G.The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. [see comment]. Lancet. 1995;346:923–6.Google Scholar
80.Schulman, EA, Dermott, KF.Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. [see comment]. Headache. 2003;43:729–33.Google Scholar
81.Dowson, A, Ball, K, Haworth, D.Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Curr Med Res Opin. 2000;16:190–7.Google Scholar
82.MacGregor, EA, Wilkinson, M, Bancroft, K.Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13: 124–7.Google Scholar
83.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:009665.Google Scholar
84.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:009663.Google Scholar
85.Chen, LC, Ashcroft, DM.Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache. 2008;48:236–47.Google Scholar
86.Ashcroft, DM, Millson, D.Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2004;13:73–82.Google Scholar
87.Poolsup, N, Leelasangaluk, V, Jittangtrong, J, Rithlamlert, C, Ratanapantamanee, N, Khanthong, M.Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther. 2005;30:521–32.Google Scholar
88.Chen, LC, Ashcroft, DM.Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache. 2007;47:1169–77.CrossRefGoogle ScholarPubMed
89.Gallagher, RM, Dennish, G, Spierings, EL, Chitra, R.A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. [see comment]. Headache. 2000;40:119–28.Google Scholar
90.Gruffyd-Jones, K, Kies, B, Middleton, A, Mulder, LJ, Rosjo, O, Millson, DS.Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur J Neurol. 2001;8:237–45.Google Scholar
91.Bomhof, M, Paz, J, Legg, N, Allen, C, Vandormael, K, Patel, K.Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol. 1999;42:173–9.Google Scholar
92.Visser, WH, Terwindt, GM, Reines, SA, Jiang, K, Lines, CR, Ferrari, MD.Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol. 1996;53:1132–7.Google Scholar
93.Goldstein, J, Ryan, R, Jiang, K, et al.Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.[see comment]. Headache. 1998;38:.737–47.Google Scholar
94.Tfelt-Hansen, P, Teall, J, Rodriguez, F, et al.Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. [see comment]. Headache. 1998;38:748–55.Google Scholar
95.Kolodny, A, Polis, A, Battisti, WP, Johnson-Pratt, L, Skobieranda, F, Rizatriptan Protocol 052 Study G. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia. 2004;24:540–6.Google Scholar
96.Spierings, EL, Gomez-Mancilla, B, Grosz, DE, Rowland, CR, Whaley, FS, Jirgens, KJ.Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001;58:944–50.Google Scholar
97.Mathew, NT, Schoenen, J, Winner, P, Muirhead, N, Sikes, CR.Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. [see comment]. Headache. 2003;43:214–22.Google Scholar
98.Sandrini, G, Farkkila, M, Burgess, G, Forster, E, Haughie, S, Eletriptan Steering C. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. [see comment]. Neurology. 2002;59:1210–7.Google Scholar
99.Goadsby, PJ, Massiou, H, Pascual, J, et al.Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007;115:34–40.Google Scholar
100.Steiner, TJ, Diener, HC, MacGregor, EA, Schoenen, J, Muirheads, N, Sikes, CR.Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003;23:942–52.CrossRefGoogle ScholarPubMed
101.Savi, L, Omboni, S, Lisotto, C, et al.A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain. 2011;12:219–26.Google Scholar
102.Tullo, V, Allais, G, Ferrari, MD, et al.Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci. 2010;31:S51–4.Google Scholar
103.Bartolini, M, Giamberardino, MA, Lisotto, C, et al.A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain. 2011;12:361–8.Google Scholar
104.Myllyla, VV, Havanka, H, Herrala, L, et al.Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998;38:201–7.Google Scholar
105.Anonymous Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenacpotassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia. 1999;19:232–40.Google Scholar
106.Anonymous A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neurol. 1992;32:177–84.Google Scholar
107.Diener, HC, Bussone, G, de Liano, H, et al.Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947–54.Google Scholar
108.Goldstein, J, Silberstein, SD, Saper, JR, et al.Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005;45:973–82.Google Scholar